Abstract: A method for controlling the state of two or more liquid crystal-based switchable windows includes in a first step providing correction data which define a relationship between a state signal and an output voltage level. The correction data is provided for each of the switchable windows and the state of the switchable windows may be adjusted according to the state signal between a minimum and maximum level. In a subsequent step, the state signal is provided which defines the desired state of one or more selected switchable windows. In a further step, a required voltage level is determined for setting the desired state based on the state signal and the respective correction data for each of the one or more selected windows. In a subsequent step d), an AC output voltage is generated having the required voltage level for each of the one or more selected windows.

Abstract: The present invention describes dibenzofuran derivatives substituted by electron-deficient heteroaryl groups, and electronic devices, especially organic electroluminescent devices, comprising these compounds as triplet matrix materials.

Abstract: Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, their use as pharmaceuticals, as well as processes of obtaining the same.

Abstract: The present disclosure describes methods of treatment of cancer in patients with altered activity or amount of a SETD2 biomarker with a treatment regimen comprising an antagonist of Programmed Death 1 receptor (PD-1).

Abstract: Method for selecting at least one viscosity changing excipient for a formulation containing at least one unknown protein via a computer includes providing a data set that describes the viscosity of several known formulations containing at least one protein and optionally at least one viscosity changing excipient; generating representations of at least one excipient; using a Machine Learning Model executed on the computer to recognize patterns in the data set to evaluate the viscosity changing effect of the viscosity changing excipient to a new formulation containing at least one unknown protein by applying the recognized patterns on provided data of the unknown protein; selecting the at least one excipient according to an acquisition criterion and applying the excipient to the unknown protein, wherein the provided data of the at least one unknown protein describe the viscosity of a protein composition containing the at least one unknown protein.

Abstract: A liquid crystal medium comprising one or more compounds of formula PT and one or more compounds of formula GF and/or UI in which the occurring groups and parameters have the meanings defined in claim 1. Also, high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.

Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

Abstract: The present disclosure provides transaminase enzymes having improved properties and are capable of reducing (1S,5R)-6,8-dioxabicyclo[3.2.1]octan-4-one with high selectivity. Also provided are polynucleotides encoding the transaminase enzymes, host cells capable of expressing the transaminase enzymes, and methods of using the transaminase enzymes to synthesize (1S,4R,5R)-6,8-dioxabicyclo[3.2.1]octan-4-amine.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Abstract: The invention discloses a synthesizing method of benzimidazole derivant and intermediate, which is characterized by the following: proceeding arylation among aryl halide and primary amine; adopting L-pro as additive, cuprous iodide as catalyst; proceeding molecular arylation coupling reaction for aryl iodide or aryl bromide and primary amine; adopting iodo phenylamine compound and bromophenylamine compound as starting material; synthesizing the material through several-step transformation.

Abstract: Liquid-crystalline (LC) media having positive dielectric anisotropy and liquid-crystal displays (LCDs) containing these media, especially displays addressed by an active matrix and in particular to LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type.

Abstract: A method of manufacturing a composition with improved quantum yield, containing at least these steps: a/ manufacturing a mixture by at least these steps: 1/ providing a semiconducting light emitting nanoparticle, 2/ adding a macromolecular compound comprising at least an anchoring group; 3/ adding an organic additive, and b/ subjecting the mixture from step a/ to irradiation with light of a wavelength in the range of 300 to 600 nm having an intensity in the range of 0.025 to 1 W/cm2 to obtain the composition; wherein the organic additive is defined by formula (Ia): M-(X—Y)2, wherein M is a divalent metal ion, X is a hydrocarbon chain, and Y is a functional group.

Abstract: A two-bit memory device having a layer structure containing in order a bottom layer, a molecular layer containing a chiral compound having at least one polar functional group, and a top layer, which is electrically conductive and ferromagnetic. The chiral compound acts as a spin filter for electrons passing through the molecular layer. The chiral compound is of flexible conformation and has a conformation-flexible molecular dipole moment. An electrical resistance of the layer structure for an electrical current running from the bottom layer to the top layer has at least four distinct states which depend on the magnetization of the top layer and on the orientation of the conformation-flexible dipole moment of the chiral compound. Furthermore, a method for operating the two-bit memory device and an electronic component containing at least one two-bit memory device.

Abstract: The present invention relates to a liquid crystalline medium comprising dichroitic dyes made of benzothiadiazoles and related extended heterocyclic derivatives, the use of said medium for optical, electro-optical and electronic purposes, in particular in devices for regulating the passage of radiation energy from an outside space into an inside space, for example in windows. The invention further relates to devices containing the liquid crystalline medium according to the invention. Some new dichroitic dyes are disclosed.

Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind PI16 and block binding of ILT3 to PI16.

Abstract: The present invention relates to an enzymatic synthesis of 4?-ethynyl-2?-deoxy nucleosides and analogs thereof, for example EFdA, that eliminates the use of protecting groups on the intermediates, improves the stereoselectivity of glycosylation and reduces the number of process steps needed to make said compounds. It also relates to the novel intermediates employed in the process.

Abstract: Provided herein are compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

Abstract: The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.

Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.

Abstract: A novel treatment regimen is provided for the treatment of autoimmune disorders. Said novel treatment regimen provides for an efficacious treatment of autoimmune disorders with an advantageous safety profile and/or a high quality of life for the patient. Said novel treatment regimen provides for an advantageous benefit-risk ratio for patients endangered by the risk of infections.